Preoperative Use of the Rho Kinase Inhibitor Ripasudil Protects the Corneal Endothelium from Trabeculectomy-Induced Damage

Artículo

Preoperative Use of the Rho Kinase Inhibitor Ripasudil Protects the Corneal Endothelium from Trabeculectomy-Induced Damage

Katsura Y et al · Dove Medical Press · 2026

Acceso abierto al texto completo

Lectura rápida. Revisá los datos básicos del recurso y luego accedé al contenido desde el botón principal. En esta ficha solo se muestra la información necesaria para identificar la obra, citarla y abrirla.

Autor / responsable

Katsura Y et al

Editorial

Dove Medical Press

Año

2026

ISSN

1177-5483

ISSN

1177-5483

Idioma

eng

Acceso al recurso

Entrá al contenido desde la opción principal o elegí otra fuente disponible.

Acceso principal

Acceso abierto al texto completo

Texto completo identificado como acceso abierto.

Abrir texto

Resumen

Descripción general del contenido del recurso.

Yamato Katsura,&ast; Hisataka Fujimoto,&ast; Masashi Takata, Hiroshi Yokoyama, Tomohiro Sekiya, Fumi Gomi Department of Ophthalmology, Hyogo Medical University, Nishinomiya, Hyogo, Japan&ast;These authors contributed equally to this workCorrespondence: Hisataka Fujimoto, Department of Ophthalmology, Hyogo Medical University, Nishinomiya, Hyogo, Japan, Tel +81-798-45-6462, Email fujimohis1000@gmail.comPurpose: Rho kinase inhibitors have emerged as treatment options for glaucoma and corneal endothelial disorders. Ripasudil, a Rho kinase inhibitor, has been approved for clinical use in glaucoma; however, further investigations are warranted for its use in the treatment of corneal endothelial disorders. We aimed to evaluate the effectiveness of preoperative ripasudil in reducing corneal endothelial damage following trabeculectomy.Patients and Methods: This retrospective observational study included a total of 139 consecutive eyes with primary open-angle glaucoma that underwent trabeculectomy; of these, 68 underwent trabeculectomy alone, whereas 71 underwent trabeculectomy combined with phacoemulsification and intraocular lens implantation. A total of 67 eyes were treated with 0.4% ripasudil eye drops twice daily for > 3 months until the day before trabeculectomy (ripasudil group). The remainder did not receive preoperative ripasudil (without-ripasudil group). No patients received ripasudil postoperatively. The primary measures included changes in corneal endothelial cell density following surgery. The mean follow-up period was 71.6 days.Results: Among the 139 trabeculectomy eyes, the ripasudil group demonstrated a significantly lower mean endothelial cell density loss (− 0.16%) than the without-ripasudil group (6.66%) following surgery (p < 0.001). Among the 71 trabeculectomy+phacoemulsification+intraocular lens implantation eyes, the ripasudil group demonstrated a significantly lower mean endothelial cell density loss (0.97%) than the without-ripasudil group (7.70%) following surgery (p < 0.05).Conclusion: Preoperative administration of ripasudil eye drops may help maintain the functional integrity of the corneal endothelium in patients with glaucoma who underwent trabeculectomy.Keywords: rho kinase, glaucoma, trabeculectomy, ripasudil

Cómo citar

Elegí el formato que necesitás y copiá la referencia al portapapeles.

APA 7

al, K. Y. E. (2026). Preoperative Use of the Rho Kinase Inhibitor Ripasudil Protects the Corneal Endothelium from Trabeculectomy-Induced Damage. https://www.dovepress.com/preoperative-use-of-the-rho-kinase-inhibitor-ripasudil-protects-the-co-peer-reviewed-fulltext-article-OPTH

MLA

al, Katsura Y et. "Preoperative Use of the Rho Kinase Inhibitor Ripasudil Protects the Corneal Endothelium from Trabeculectomy-Induced Damage." 2026. https://www.dovepress.com/preoperative-use-of-the-rho-kinase-inhibitor-ripasudil-protects-the-co-peer-reviewed-fulltext-article-OPTH.

Chicago

al, Katsura Y et. 2026. "Preoperative Use of the Rho Kinase Inhibitor Ripasudil Protects the Corneal Endothelium from Trabeculectomy-Induced Damage.". https://www.dovepress.com/preoperative-use-of-the-rho-kinase-inhibitor-ripasudil-protects-the-co-peer-reviewed-fulltext-article-OPTH.

Harvard

al, K. Y. E. 2026, Preoperative Use of the Rho Kinase Inhibitor Ripasudil Protects the Corneal Endothelium from Trabeculectomy-Induced Damage, Dove Medical Press, available at: https://www.dovepress.com/preoperative-use-of-the-rho-kinase-inhibitor-ripasudil-protects-the-co-peer-reviewed-fulltext-article-OPTH [Accessed 29 Jun. 2026].

Compartir e imprimir

Guardá la ficha, copiá su enlace permanente o imprimila como PDF.

Exportar referencia

Si usás un gestor bibliográfico, podés exportar el registro en los formatos más comunes.

RIS BibTeX

Detalles del recurso

Información bibliográfica útil para confirmar que se trata del material correcto.

Título: Preoperative Use of the Rho Kinase Inhibitor Ripasudil Protects the Corneal Endothelium from Trabeculectomy-Induced Damage

Autor / colaboradores: Katsura Y et al

Editorial: Dove Medical Press

Año de publicación: 2026

ISSN: 1177-5483

ISSN: 1177-5483

Idioma: eng

Materias

Explorá otros recursos relacionados a partir de estas materias.

Rho kinase; glaucoma; trabeculectomy; ripasudil